Induction/consolidation chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies are associated with treatment-related risks such as infections. The predominant types of infections are blood stream infections (BSIs) and respiratory tract infections. We prospectively compared infectious complications after induction/consolidation chemotherapy versus allogeneic HSCT in a directly comparable setting with both groups being hospitalized on the same ward. From July 2003 until June 2008, 492 hospitalizations of 321 patients took place; 237 chemotherapies and 255 HSCTs were performed. We observed 49 (20.7%) BSIs, 70 (29.5%) pneumonias and 11 (4.6%) probable or proven invasive mould infections in the chemotherapy group. In the HSCT group we detected 70 (27.5%) BSIs, 71 (27.8%) pneumonias and 14 (5.4%) probable or proven invasive mould infections. There was a trend toward more transfers to the intensive care unit (OR 1.61; 95%CI 0.95-2.72; P ¼ 0.074) and BSIs (OR 1.45; 95%CI 0.95-2.22; P ¼ 0.079) after HSCT; 44 (13.7%) patients died. In-hospital mortality was significantly higher in the HSCT group (OR 2.39; 95%CI 1.22-4.68; P ¼ 0.010). We conclude that the risk of pneumonia and invasive mould infection is comparable after induction/ consolidation chemotherapy and allogeneic HSCT. However, there was a trend for more BSIs and intensive care unit stays and a higher mortality in the latter.
Introduction
Induction/consolidation chemotherapy and hematopoietic stem cell transplantation (HSCT) are established therapeutic options for patients with hematological malignancies. Despite anti-infective prophylaxis, infections remain an important complication during treatment-associated neutropenia. [1] [2] [3] In neutropenia, the two predominant types of infections are blood stream infections (BSI) and respiratory tract infections. Known risk factors for infectious complications in addition to neutropenia are acute myeloid leukemia (AML) as underlying disease, severe mucositis, immunosuppressive agents and graft versus host disease. [4] [5] [6] [7] Blood stream infections are the most frequent single reason for fever in neutropenia in hematological patients with a rate of 29-43%. [8] [9] [10] In similar patient populations, incidence rates of 3-9% were reported for pneumonia 6, 7, [11] [12] [13] and 3-12% for invasive aspergillosis. 1, 5, 14, 15 The highest infection-attributed mortality is reported for invasive fungal infections (40-60% for invasive candidiasis and 60-99% for invasive aspergillosis). [16] [17] [18] [19] Generally, it is thought that infectious complications are more severe and more frequent after allogeneic HSCT compared with induction/consolidation chemotherapy, albeit no studies examined this question. In a directly comparable setting, that is all study patients hospitalized on the same ward, this prospective study aims at analyzing the incidence of BSIs, pneumonias and invasive mould infections in patients with hematological malignancies receiving induction/consolidation chemotherapy or allogeneic HSCT.
Patients and methods

Study design and study population
In this prospective observational cohort study we included all adult patients (X16-years old) admitted to the hematology ward for induction/consolidation chemotherapy or allogeneic HSCT for hematological malignancies between July 2003 and June 2008. Data of BSIs, pneumonia and invasive mould infections were recorded. The patients with allogeneic HSCT were also part of the surveillance program of the German National Reference Center for Surveillance of nosocomial infections (KISSGerman Hospital Infection Surveillance System) collecting data of BSIs and pneumonia. All patients were hospitalized on the hematoloxy ward at the University Hospital Basel that runs 12 beds with about 180 hospitalizations and 4200 patient days per year.
Data collection
Using a standardized case report form, we prospectively collected information on demographic data, the hematological diagnosis and therapy, duration of neutropenia, type of vascular access and the following complications: pneumonia, primary BSI, invasive mould infection, transfer to intensive care unit, intubation and in-hospital death. We did not routinely perform a post discharge follow-up examination.
Supportive care measures
Each patient was hospitalized in a single room that was supplied with high efficiency particulate air filters. Antimicrobial prophylaxis during hospitalization consisted of fluconazole (400 mg once per week) and either oral valacyclovir (two 500 mg doses twice daily) or intravenous acyclovir (5 mg/kg twice daily) in patients with a positive HSV serology. Trimethoprim-sulfamethoxazole (160 and 800 mg, respectively, three times weekly) was given to the patients undergoing allogeneic HSCT but not to the patients receiving induction/consolidation chemotherapy.
Every patient without Port-a-Cath or tunneled catheter had a triple lumen, first generation chlorhexidine/ sulfadiazine-coated polyurethane central venous catheter placed in the subclavian vein within the first days of their hospitalization.
Fever in neutropenia, defined as tympanal temperature X38.5 1C once or X38.0 1C twice within an hour lead to a thorough clinical examination and collection of blood cultures, followed by the initiation of an empiric antibiotic therapy (either cefepime in combination with amikacine or piperacillin-tazobactam as a monotherapy). In case of persistent fever without a focus of infection, a computed tomography of the chest was performed. Furthermore, empirical antibiotics were switched after 5 days to either piperacillin-tazobactam or meropenem and antifungal treatment was added according to the IDSA guidelines 2002. 20 
Blood cultures
When fever in neutropenia occurred, two pairs of blood cultures (a pair consisting of one aerobic and one anaerobic bottle) were collected; 8-10 ml of blood was drawn through the central venous line and injected into each blood culture bottle. If a catheter-related infection was assumed, additional blood cultures were drawn by peripheral venous puncture. Blood cultures were incubated in an automated continuous monitoring system (BACTEC: BD Diagnostic Systems, Sparks, MD, USA) or BacT/ALERT 3D: BioMe´rieux, Durham, NC, USA).
Definitions
Neutropenia was defined as an absolute neutrophil count o0.5 Â 10 9 cells/l or o1 Â 10 9 cells/l with an anticipated drop below 0.5 Â 10 9 cells/l or an absolute white blood cell count o1 Â 10 9 cells/l. The end of neutropenia was defined as absolute white blood cell count 41 Â 10 9 cells/l for 3 days.
Primary blood stream infection was defined according to the Centers for Disease Control and Prevention (CDC) definitions including clinical and microbiological criteria 21 as follows: isolation of a recognized pathogen from X1 blood culture or fever, shivering, hypotension and one of the followings: isolation of a common skin contaminant (coagulase-negative staphylococci, Coryne-and Propionibacteria) from two separate blood cultures that was unrelated to an infection at another site or the isolation of a common skin contaminant from one blood culture for patients with an intravascular device for whom a physician initiated or continued appropriate antimicrobial therapy. If the central venous line or mucositis were considered to be the focus, they were still included in primary BSIs.
Definition of pneumonia was based on CDC guidelines with modifications for pneumonia in neutropenia as described by Carlisle 22 because of the frequent absence of clinical manifestations due to the lack of leukocyte response in neutropenic patients. According to these definitions, pneumonia was diagnosed on the basis of the following criteria: (i) fever and (ii) new or worsening infiltrates revealed by chest radiograph or thoracic computed tomography, or presence of at least two of the following signs or symptoms: Production of sputum, cough, dyspnea, rhonchi or rales; polymorphonuclear leukocytes on a sputum Gram stain or pleural rub.
Invasive pulmonary mould infections were classified according to the EORTC/MSG definitions. 23 These definitions lead to an overlap of pneumonia and possible pulmonary mould infection. Therefore, we included the latter in the pneumonia group. Bronchoscopy was performed only in selected patients.
Statistical analysis
For comparisons of categorial data the w 2 test and for comparisons of non-categorial variables the Mann-Whitney U-test was performed. The rates of infections were calculated as incidence per 1000 days of neutropenia 24 and as incidence densities per 100 hospitalizations. Survival patterns were displayed using Kaplan-Meier plots of cumulative survival probabilities analyzing the probability of infection after onset of neutropenia. Patients were censored at date of discharge or death.
Several patients were treated with induction/consolidation chemotherapy and by allogeneic HSCT in two or more episodes. Therefore, w 2 tests or Mann-Whitney U-tests need to be adjusted: We used a matched design (McNemar test) to compare the incidence rate of infections between induction/consolidation chemotherapy and HSCT in a subgroup of patients with both types of hospitalization available. For this analysis, all patients with an episode of chemotherapy at our institution before the HSCT episode were included.
A P-value of p0.05 (two-tailed) was considered statistically significant. All analyses were performed using SPSS 15.0 statistical software package (SPSS Inc., Chicago, IL, USA). (Table 1) . Totally, 237 induction/ consolidation chemotherapies and 255 allogeneic HSCTs were performed. The two groups were comparable by means of gender, that is 183 (57%) being male and 138 (43%) being female patients, respectively. The median age of the patients was 48 years. The median age in the allogeneic HSCT group (45 years) was significantly lower than in the chemotherapy group (54 years; Po0.001).
Results
Patient characteristics
The majority of patients, namely 148 (46.1%) suffered from AML, followed by 49 (15.3%) patients with acute lymphatic leukemia and 23 (7.2%) with myelodysplastic syndrome. Acute myeloid leukemia was the most frequent underlying disease in both treatment groups, that is 161/237 (67.9%) in the induction/consolidation chemotherapy group and 106/255 (41.6%) in the allogeneic HSCT group. In AML patients the treatment modality was significantly more frequently a chemotherapy than allogeneic HSCT (Po0.001), as these patients receive 2-3 chemotherapy cycles before an allogeneic HSCT.
The median duration of the hospital stay in the HSCT group (31 days) was significantly longer than in the chemotherapy group (28 days) (P ¼ 0.001, Table 1 ). Overall, during 458 episodes at least one period of neutropenia occurred with a median duration of 15.5 days adding up to a total of 8904 neutropenic days. The duration of neutropenic episodes was significantly higher in the group hospitalized for chemotherapy compared with patients after HSCT (18 and 13 days, respectively; Po0.001).
The characteristics of the 46 patients used for the McNemar analysis were as follows: 23 patients (50%) were female with a median age of 47 years. The majority (32 patients, 69.6%) suffered from AML.
Infectious complications
Of note, there was a slight trend for more primary BSIs in the allogeneic HSCT group than in the chemotherapy group (OR 1.45; 95%CI 0.95-2.22; P ¼ 0.079.
Pneumonia occurred in both treatment groups with a similar incidence rate (70/237 in the chemotherapy group and 71/255 in the allogeneic HSCT group). Approximately half of the pneumonia cases in each treatment group were classified as possible invasive mould infection. Probable and proven invasive mould infections were also equally diagnosed after induction/consolidation chemotherapy and after allogeneic HSCT (11/237, 4.6% and 14/255, 5.4%, respectively).
The matched McNemar test for patients in both groups did not show a statistically significant difference in infectious complications between the two groups (Table 3) .
Overall, the incidence of any infectious complication, that is primary BSI, pneumonia and/or invasive mould infection, was similar (43.5 and 41.6%, respectively).
The most frequently isolated pathogens in primary BSIs were Gram-positive cocci (62.7%, mostly coagulase-negative staphylococci), followed by Gram-negative bacteria (22.4%, predominantely Escherichia coli) and Candida spp. (9.7%, mainly C. albicans and krusei). Only in the minority of pneumonias a pathogen was isolated, namely in 23/148 (15.5%) episodes of pneumonia with predominantely Gram-negative pathogens, 8 followed by viruses, 7 mostly 
Infections-chemotherapy vs allogeneic HSCT C Orasch et al
Respiratory Syncytial Virus (RSV). Of note, in two pneumonias, Pneumocystis jiroveci was isolated. Analyzing the rates of infections per 1000 neutropenic days, we observed similar results in the two groups for primary BSIs and a higher incidence for pneumonias in the chemotherapy group (Table 4) . Figure 1 shows the Kaplan-Meyer curve for the probability of infection-free survival after onset of neutropenia in patients receiving either chemotherapy or allogeneic HSCT. The probability of infection-free survival was similar in both groups (P ¼ 0.519). The slightly higher risk of infection in the HSCT group during the first days after onset of neutropenia is getting similar after the 15th day.
Infection-free survival and survival
In 68 (13.8%) hospitalizations, patients had to be transferred to the intensive care unit. There was a trend toward more frequent transfers of patients to the intensive care unit after allogeneic HSCT than after induction/ consolidation chemotherapy (OR 1.61; 95%CI 0.95-2.72; P ¼ 0.074). The McNemar test showed no significant difference (P ¼ 0.289).
Overall, 44 (13.7%) of all patients died during hospitalization. In-hospital mortality was significantly higher in patients hospitalized for allogeneic HSCT compared with patients receiving induction/consolidation chemotherapy (OR 2.39; 95%CI 1.22-4.68; P ¼ 0.010) ( Table 5 ). In 31 patients (70%) an autopsy was performed. In the other 13 patients, the reason of death was assigned by evaluating the patient's chart and the infectious diseases consultation. Fifteen patients (34%) died of an infection, mainly pneumonia. In three patients (7%), the association of death with an infectious event was possible, but not definite. In the remaining 26 patients (59%), the most common reasons of death were diffuse alveolar damage, cerebral events (hemorrhage, ischemia, toxic encephalopathy), graft versus host disease, venoocclusive disease or progressive underlying disease.
Discussion
Our study shows that patients with neutropenia because of induction/consolidation chemotherapy for hematological malignancies have an equal risk for pneumonia and invasive mould infection as patients after allogeneic HSCT. However, there is a tendency toward more BSIs and intensive care transfers and a significantly higher mortality after allogeneic HSCT. Published rates of BSIs in patients undergoing HSCT are reported to be higher than rates from studies including patients receiving induction/consolidation chemotherapies (29-39% versus 10-30%, respectively). 10, 13, [25] [26] [27] In our analysis, there was a trend toward more BSIs in the allogeneic HSCTs, without a statistically significant difference in the McNemar model, which may be explained by the small number of patients available for this analysis.
Compared with the published literature, the overall rate of BSIs after HSCT was slightly lower (28% versus 29-39%) whereas the incidence of BSIs in chemotherapy (19% versus 10-30%) was within the range described in the literature. [8] [9] [10] 13, [25] [26] [27] Our rates of BSIs are in the range of centers applying prophylactic antibiotics even though we do not. 6 Bucaneve et al. 3 reported a reduction in BSIs from 34 to 18% by use of an antibiotic prophylaxis with levofloxacin during neutropenia after autologous stem cell transplant or chemotherapy. The reasons for our relatively low incidence of BSIs can only be hypothesized. Possible explanations may be that only primary BSIs were included in our study or the routine use of chlorhexidine/sulfadiazine-coated central venous catheters for venous access in our hematological patients, which has proved to reduce catheter-related infections. 28 The microbiological spectrum of BSIs in our study corresponds to the published literature with predominately coagulase-negative staphylococci. 3 Of note, we did neither isolate methicillin-resistant Staphylococcus aureus nor highly resistant Gram-negative bacteria in the hematological unit. This indicates the benefit of a restrictive antibiotic policy based on a close collaboration of infectious diseases specialists, hospital epidemiology and hematologists. 29 Compared with the literature, we have less BSIs caused by Gram-negative bacteria (22.4% versus 27-38%) even though we do not use antibiotic prophylaxis with a quinolone. 30, 31 We recorded 11 episodes of candidemia (9.7% of all BSIs), which is comparable with the literature despite the fact that we perform a rather unique prophylaxis with fluconazole 400 mg once weekly. 9, 32 The incidence of pneumonia was 27.8% in the allogeneic HSCT group and 29.5% in the chemotherapy group, which is higher than reported in the literature (3-9%). 7, [11] [12] [13] The same is true when calculated per 1000 days of neutropenia (6.1 in allogeneic HSCT in the literature versus 12.09 in our study). 6 One explanation might be the routinely performed thoracic CT scans instead of conventional radiographs for diagnostic work-up of fever in neutropenia with a correspondingly higher sensitivity for infiltrates. As reported in the literature, we were rarely able to isolate a causative microorganism in patients with pneumonia. The reasons might be that bronchoalveolar lavage was only performed for selected patients and usually only after the start of antibiotic treatment. We found three patients with an RSV infection of the lower respiratory tract, an infection with a high mortality in severely immunosuppressed patients. 33 Two of these three patients died because of the RSV pneumonia. The two cases of P. jirovecii pneumonia occurred in patients with induction chemotherapy not taking a trimethoprim-sulfamethoxazole prophylaxis.
Proven and probable invasive mould infections were similar in both groups (4.6% for chemotherapy and 5.4% for allogeneic HSCT) and predominantely caused by Aspergillus spp. The incidence of invasive mould infections at our center is comparable to other studies. 1, 5, 14, 15 The strength of this study is its prospective design in a standardized setting with all patients being hospitalized on the same ward and therefore being less confounded for a comparative analysis. As a single-center study, important conclusions on the local level can be made. However, this might be a disadvantage, because our results cannot be generalized to other centers. Further limitations are the still quite small number of hospitalizations with a risk of missing rare infections that are important on an individual level. Another difficulty is that most patients were hospitalized several times, which might have biased the results. The number of patients for the McNemar analysis was small; therefore, the possibility to find significant differences between the two groups was limited.
In conclusion, we show that the neutropenic period after induction/consolidation chemotherapy bears a comparable risk for pneumonias and invasive mould infections, whereas the risk of primary BSIs may be marginally lower than in the HSCT group. These findings may influence the alertness for infectious complications after induction/consolidation chemotherapy.
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